Atypical antipsychotics - How not to market a medicine

Pharmaceutical Journal

Volumn 261, Issue 7020, 1998, Pages 778-

  Maidment, Ian ^a  

^a NORFOLK AND SUFFOLK NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; QUETIAPINE; RISPERIDONE; SERTINDOLE;

ARTICLE; DRUG COST; DRUG EFFICACY; DRUG MARKETING; HUMAN; MAJOR CLINICAL STUDY; SCHIZOPHRENIA;

EID: 7844237161     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Thomas CS, Lewis S. Which atypical antipsychotic? Br J Psychiatr 1998;172:106-9.
2. Taylor D, Drumraond S, Pendlebury J. Olanzapine in practice. Psychiatr Bull 1998;22:552-4.
3. Kelly C, McCreadie RG, MacEwan T, Carey S. Nithsdale schizophrenia surveys 17. BrJ Psychiatr 1998;172: 513-7.
4. Gelder M, Gath D, Mayou R, Cowen P. Oxford textbook of psychiatry (3rd ed). Oxford: Oxford University Press, 1996:404-5.
5. Mir S, Taylor D. Issues in schizophrenia. Pharm J 1998;261:55-8.
6. Kerwin R, Taylor D. New antipsychotics. CNS Drugs 1996;6:71-82.
7. Taylor D, Holmes R, Hilton T, Paton C. Evaluating and improving the quality of risperidone prescribing. Psychiatr Bull 1997;21:680-3.